Copyright © 2012 Ambroise Marçais et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. Shimoyama, “Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984–87),” British Journal of Haematology, vol. 79, no. 3, pp. 428–437, 1991. View at Scopus
2. K. Tsukasaki, O. Hermine, A. Bazarbachi et al., “Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 453–459, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. Y. Takasaki, M. Iwanaga, Y. Imaizumi et al., “Long-term study of indolent adult T-cell leukemia-lymphoma,” Blood, vol. 115, no. 22, pp. 4337–4343, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. M. Shimoyama, K. Ota, M. Kikuchi et al., “Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia,” Journal of Clinical Oncology, vol. 6, no. 7, pp. 1088–1097, 1988. View at Scopus
5. K. Tsukasaki, K. Tobinai, M. Shimoyama et al., “Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan clinical oncology group study (JCOG9109),” International Journal of Hematology, vol. 77, no. 2, pp. 164–170, 2003. View at Scopus
6. Y. Yamada, M. Tomonaga, H. Fukuda et al., “A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan clinical oncology group study 9303,” British Journal of Haematology, vol. 113, no. 2, pp. 375–382, 2001. View at Publisher · View at Google Scholar · View at Scopus
7. K. Tsukasaki, A. Utsunomiya, H. Fukuda et al., “VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5458–5464, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. M. Hishizawa, J. Kanda, A. Utsunomiya et al., “Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study,” Blood, vol. 116, no. 8, pp. 1369–1376, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. N. Uike, R. Tanosaki, A. Utsunomiya, I. Choi, and J. Okamura, “Can allo-SCT with RIC cure ATLL? long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level,” Retrovirology, vol. 8, supplement 1, pp. A33–A33, 2011. View at Publisher · View at Google Scholar
10. P. S. Gill, W. Harrington, M. H. Kaplan et al., “Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine,” New England Journal of Medicine, vol. 332, no. 26, pp. 1744–1748, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. O. Hermine, D. Bouscary, A. Gessain et al., “Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa,” New England Journal of Medicine, vol. 332, no. 26, pp. 1749–1751, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. A. Bazarbachi and O. Hermine, “Treatment with a combination of zidovudine and α-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 13, supplement 1, pp. S186–S190, 1996.
13. O. Hermine, I. Allard, V. Lévy, B. Arnulf, A. Gessain, and A. Bazarbachi, “A prospective phase II clinical trial with the use of zidovudine and interferon-α in the acute and lymphoma forms of adult T-cell leukemia/lymphoma,” Hematology Journal, vol. 3, no. 6, pp. 276–282, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. J. D. White, G. Wharfe, D. M. Stewart et al., “The combination of zidovudine and interferon α-2B in the treatment of adult T-cell leukemia/lymphoma,” Leukemia and Lymphoma, vol. 40, no. 3-4, pp. 287–294, 2001. View at Scopus
15. E. Matutes, G. P. Taylor, J. Cavenagh et al., “Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: Response and outcome in 15 patients,” British Journal of Haematology, vol. 113, no. 3, pp. 779–784, 2001. View at Publisher · View at Google Scholar · View at Scopus
16. A. Bazarbachi, Y. Plumelle, J. Carlos Ramos et al., “Meta-analysis on the use of zidovudine and interferon-α in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4177–4183, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. A. Bazarbachi, M. E. El-Sabban, R. Nasr et al., “Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells,” Blood, vol. 93, no. 1, pp. 278–283, 1999. View at Scopus
18. M. E. El-Sabban, R. Nasr, G. Dbaibo et al., “Arsenic-interferon-α-triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-κ B activation,” Blood, vol. 96, no. 8, pp. 2849–2855, 2000. View at Scopus
19. R. Nasr, A. Rosenwald, M. E. El-Sabban et al., “Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells,” Blood, vol. 101, no. 11, pp. 4576–4582, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. H. El Hajj, M. El-Sabban, H. Hasegawa et al., “Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia,” Journal of Experimental Medicine, vol. 207, no. 13, pp. 2785–2792, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. G. Kchour, M. Tarhini, M. M. Kooshyar et al., “Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon α, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL),” Blood, vol. 113, no. 26, pp. 6528–6532, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
22. F. Suarez, A. Marcais, D. Ghez, et al., “Arsenic trioxyde in the treatment of HTLV1 associated ATLL,” Retrovirology, vol. 8, supplement 1, p. A59, 2011. View at Publisher · View at Google Scholar
23. T. A. Waldmann, J. D. White, C. K. Goldman et al., “The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia,” Blood, vol. 82, no. 6, pp. 1701–1712, 1993. View at Scopus
24. T. A. Waldmann, J. D. White, J. A. Carrasquillo et al., “Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac,” Blood, vol. 86, no. 11, pp. 4063–4075, 1995. View at Scopus
25. I. C. Moura, Y. Lepelletier, B. Arnulf et al., “A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients,” Blood, vol. 103, no. 5, pp. 1838–1845, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
26. A. Utsunomiya, K. Tobinai, K. Yamamoto, et al., “Promising results of an anti-CCR4 antibody, KW-0761, for relapsed adult T-cell leukemia-lymphoma (ATL),” Retrovirology, vol. 8, supplement 1, p. A40, 2011. View at Publisher · View at Google Scholar
27. O. A. O'Connor, B. Pro, L. Pinter-Brown et al., “Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1182–1189, 2011. View at Publisher · View at Google Scholar · View at PubMed
28. E. A. Olsen, Y. H. Kim, T. M. Kuzel et al., “Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3109–3115, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. S. J. Whittaker, M. F. Demierre, E. J. Kim et al., “Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 28, no. 29, pp. 4485–4491, 2010. View at Publisher · View at Google Scholar · View at PubMed
30. R. L. Piekarz, R. Frye, H. M. Prince et al., “Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma,” Blood, vol. 117, no. 22, pp. 5827–5834, 2011. View at Publisher · View at Google Scholar · View at PubMed
31. J. Ramos, N. Toomey, L. Diaz, P. Ruiz, G. Barber, and W. Harrington, “Targeting HTLV-I latency in adult T-cell leukemia/lymphoma,” Retrovirology, vol. 8, supplement 1, p. A48, 2011. View at Publisher · View at Google Scholar
32. C. E. Dearden, E. Matutes, B. Cazin et al., “High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H,” Blood, vol. 98, no. 6, pp. 1721–1726, 2001. View at Publisher · View at Google Scholar · View at Scopus
33. A. Mone, S. Puhalla, S. Whitman et al., “Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α-refractory adult T-cell leukemia,” Blood, vol. 106, no. 10, pp. 3380–3382, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. F. Ravandi, A. Aribi, S. O'Brien et al., “Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5425–5430, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. G. Dueck, N. Chua, A. Prasad et al., “Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-hodgkin lymphoma,” Cancer, vol. 116, no. 19, pp. 4541–4548, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. A. Hodson, N. Mir, A. Pagliuca, et al., “Addition of anti-viral therapy to chemotherapy improves overall survival in acute and lymphomatous adult T-cell leukaemia/lymphoma (ATLL),” in Proceedings of the ASH Annual Meeting Abstracts, vol. 116, p. 3961, 2010.
37. A. Datta, M. Bellon, U. Sinha-Datta et al., “Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence,” Blood, vol. 108, no. 3, pp. 1021–1029, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. J. M. Flaman, T. Frebourg, V. Moreau et al., “A simple p53 functional assay for screening cell lines, blood, and tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 3963–3967, 1995. View at Scopus